Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

Nilar Lwin, Michael Boyle, Joshua S. Davis

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

    Original languageEnglish
    Article numberofy027
    Pages (from-to)1-3
    Number of pages3
    JournalOpen Forum Infectious Diseases
    Volume5
    Issue number2
    DOIs
    Publication statusPublished - 1 Feb 2018

    Fingerprint

    Immune Reconstitution Inflammatory Syndrome
    Coinfection
    Adrenal Cortex Hormones
    HIV
    Prednisolone
    Steroids
    Infliximab
    Adalimumab
    Therapeutics

    Cite this

    @article{1d7331863f85472f8f8f6732fcfaed65,
    title = "Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection",
    abstract = "Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.",
    keywords = "Adalimumab, HIV, Immune reconstitution, Steroid, Tuberculosis",
    author = "Nilar Lwin and Michael Boyle and Davis, {Joshua S.}",
    year = "2018",
    month = "2",
    day = "1",
    doi = "10.1093/ofid/ofy027",
    language = "English",
    volume = "5",
    pages = "1--3",
    journal = "Open Forum Infectious Diseases",
    issn = "2328-8957",
    publisher = "Oxford University Press",
    number = "2",

    }

    Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection. / Lwin, Nilar; Boyle, Michael; Davis, Joshua S.

    In: Open Forum Infectious Diseases, Vol. 5, No. 2, ofy027, 01.02.2018, p. 1-3.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Adalimumab for corticosteroid and infliximab-resistant immune reconstitution inflammatory syndrome in the setting of TB/HIV coinfection

    AU - Lwin, Nilar

    AU - Boyle, Michael

    AU - Davis, Joshua S.

    PY - 2018/2/1

    Y1 - 2018/2/1

    N2 - Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

    AB - Corticosteroids are the mainstay of therapy for immune reconstitution inflammatory syndrome (IRIS). However, little is known about how to treat IRIS unresponsive to steroids. We report a patient with HIV-TB coinfection who was unresponsive to first prednisolone and then infliximab but whose IRIS resolved with adalimumab.

    KW - Adalimumab

    KW - HIV

    KW - Immune reconstitution

    KW - Steroid

    KW - Tuberculosis

    UR - http://www.scopus.com/inward/record.url?scp=85044416487&partnerID=8YFLogxK

    U2 - 10.1093/ofid/ofy027

    DO - 10.1093/ofid/ofy027

    M3 - Article

    VL - 5

    SP - 1

    EP - 3

    JO - Open Forum Infectious Diseases

    JF - Open Forum Infectious Diseases

    SN - 2328-8957

    IS - 2

    M1 - ofy027

    ER -